MedPath

Frameless Stereotactic Radiosurgery for Brain Metastases

Phase 1
Conditions
Brain Metastases
Interventions
Device: Frameless Stereotactic Radiosurgery with radiation mask
Registration Number
NCT01476878
Lead Sponsor
Alberta Health services
Brief Summary

The investigators plan to study high dose, single treatment radiation, using a plastic mask instead of a head frame that pins into a patient's skull. The investigators need to (1) quantify set-up accuracy and patient motion during radiation treatment and (2) ensure that without the head frame the tumour control rate and risk of complications are similar to our previous experience using the head frame.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients with brain metastases from a biopsy-proven primary extra-cranial tumor site, excluding lymphoma, germ cell, and small cell lung carcinoma histologies.
  • One to four metastases, and all lesions < 3.5 cm in maximal diameter. Extracranial metastases is of minimal volume or stable with treatment. - Karnofsky performance status ≥ 70
Exclusion Criteria
  • None of the lesions is abutting or within critical neurological structures: *brainstem

    • optic chiasm
    • eye, and optic nerve.
  • The clearance between metastatic lesions and all critical structures must be at least 2 mm.

  • Patients must not have leptomeningeal disease.

  • Contraindications to imaging or radiation (e.g. pregnancy, elevated serum creatinine, allergy to contrast agents, severe claustrophobia, metal particles in the eye).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Open ArmFrameless Stereotactic Radiosurgery with radiation maskEach study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
Primary Outcome Measures
NameTimeMethod
Quantification of patient movement occurring during treatment.overall
Secondary Outcome Measures
NameTimeMethod
Local tumour controloverall
risk of complication (radionecrosis)overall

Trial Locations

Locations (1)

Tom Baker Cancer Centre

🇨🇦

Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath